Rhenovia files patents for new treatment of Huntington’s disease based on its biosimulation platform

06-Jun-2012 - Rhenovia Pharma announced the filing of patents of a new method, a drug candidate, RHEDAR (TM) and a novel chemical series for treating Huntington’s disease (HD). RHEDAR is a significant step forward in the use of novel modes of action using Modeling and Simulation (M&S) for cost-effective drug ...

Rhenovia launches drug discovery programs in rare, orphan and neglected neurodegenerative diseases

Neurological specialist will carry out research based on its unique biosimulation platforms

21-Mar-2012 - Rhenovia Pharma announced that it has initiated drug research programs in rare, orphan and neglected diseases.Rare diseases are defined as those affecting fewer than one in 2,000. Eighty per cent are caused by genetic defects but they also include rare forms of cancer, auto-immune disorders, ...

Rhenovia Pharma opens first US office

Expands activities to the Greater Boston Area

26-Jan-2012 - Rhenovia Pharma SAS announced its first international subsidiary, Rhenovia Inc., incorporated in Delaware. Rhenovia’s new operation will be based in the Greater Boston Area with offices in Cambridge, Massachusetts.Rhenovia Inc. will enable the widespread use of its unique biosimulation technology ...

Rhenovia signs an R&D contract with Sodiaal-Candia for studying the nutritional and therapeutic value of milk and its derivatives

28-Apr-2011 - Rhenovia Pharma SAS announced the signing of a research-and-development contract with Sodiaal-Candia. The contract is aimed at identifying new avenues of research for better understanding the beneficial effects on human health of the milk components and its derivatives. The research will focus in ...

Rhenovia wins contract to lead USD 3.75 million biosimulation project

15-Apr-2010 - Rhenovia Pharma SAS announced that it has been named leader of RHENEPI, a EUR 2.5 million (USD 3.75M) project. The goals of RHENEPI are to develop and obtain experimental validation for an epilepsy biosimulation platform that can be used for the discovery of new antiepileptic drugs and the ...

Rhenovia opens its biosimulation platform for collaborative projects to optimize CNS drug discovery and development

07-May-2009 - Rhenovia Pharma SAS announced that it is offering its first biosimulation platform for use in collaborative projects to optimize drugs targeting diseases of the central nervous system. The Rhenovia platform is being made available as part of the company's RHEDDOS program. Developed over the last ...